# A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct06481891` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06481891](<https://clinicaltrials.gov/study/NCT06481891>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06481891

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT06481891. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-24 (actual); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT06481891, source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)
- Started: 2024-09-24 (actual) (ClinicalTrials.gov record NCT06481891, source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06481891, source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06481891, source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)
- Countries: United States; Argentina; Belgium; Brazil; Bulgaria; Croatia; Czechia; France; Georgia; Germany; Hungary; Israel; Italy; Poland; Portugal; Romania; Serbia; Sweden; United Kingdom (ClinicalTrials.gov record NCT06481891, source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06481891-2026-08-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- Acronym: SONATA-HCM
- Condition: Obstructive Cardiomyopathy, Hypertrophic
- Condition: Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)

## Provenance

Content hash: d493256891ec6be3b24827fc80c2646989ed78a62faf207ddcc2d0d81799b545
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
